Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Trial Profile

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Imidafenacin (Primary) ; Mirabegron (Primary) ; Propiverine (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 13 Dec 2018 Last checked against ClinicalTrials.gov record.
    • 03 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 31 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top